PMC:7102591 / 21823-23181
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
657 | 235-240 | Gene | denotes | ACE 2 | Gene:59272 |
658 | 738-746 | Species | denotes | patients | Tax:9606 |
659 | 40-51 | Chemical | denotes | chloroquine | MESH:D002738 |
660 | 459-470 | Chemical | denotes | chloroquine | MESH:D002738 |
661 | 770-781 | Chemical | denotes | chloroquine | MESH:D002738 |
662 | 1023-1041 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
663 | 1095-1106 | Chemical | denotes | chloroquine | MESH:D002738 |
664 | 421-439 | Disease | denotes | SARS CoV infection | MESH:C000657245 |
665 | 610-618 | Disease | denotes | COVID-19 | MESH:C000657245 |
666 | 886-895 | Disease | denotes | pneumonia | MESH:D011014 |
667 | 1332-1352 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T77 | 76-85 | Body_part | denotes | endosomal | http://purl.org/sig/ont/fma/fma67180 |
T78 | 108-112 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T79 | 832-836 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T21 | 832-836 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid_AGAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p51644s32 | 187-209 | MPA | denotes | terminal glycosylation |
p51645s8 | 315-332 | MPA | denotes | -receptor binding |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T248 | 421-425 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T249 | 430-439 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T250 | 610-618 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T251 | 886-895 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T252 | 1332-1340 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T253 | 1343-1352 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T146 | 102-107 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T147 | 108-112 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T148 | 155-163 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T149 | 310-315 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T150 | 347-348 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T151 | 444-445 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T152 | 471-474 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T153 | 582-588 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T154 | 832-836 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T155 | 832-836 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T156 | 907-908 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T157 | 909-914 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T158 | 1224-1225 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T177 | 40-51 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T178 | 373-377 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T179 | 459-470 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T180 | 675-680 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T181 | 770-781 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T182 | 1023-1041 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T183 | 1095-1106 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T41 | 108-119 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell fusion |
T42 | 108-119 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell fusion |
T43 | 108-119 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
T44 | 108-119 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
T45 | 146-163 | http://purl.obolibrary.org/obo/GO_0038024 | denotes | receptor activity |
T46 | 187-209 | http://purl.obolibrary.org/obo/GO_0033578 | denotes | terminal glycosylation |
T47 | 196-209 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T123 | 0-260 | Sentence | denotes | At clinically admissible concentrations chloroquine is able to increase the endosomal pH required for virus/cell fusion, to inhibit the toll-like receptor activity, and to interfere with terminal glycosylation of the cellular receptor ACE 2 [[88], [89], [90]]. |
T124 | 261-440 | Sentence | denotes | All these functions may negatively influence the virus-receptor binding, resulting in a potential effect of the drug on both entry and post-entry stages of the SARS CoV infection. |
T125 | 441-702 | Sentence | denotes | As a consequence, chloroquine has recently been included in at least 10 randomized controlled trials currently ongoing in China, where it is tested for the treatment of COVID-19 under various combination protocols with the anti-viral drugs mentioned above [91]. |
T126 | 703-1007 | Sentence | denotes | Interim results from more than 100 patients have demonstrated that chloroquine is superior to the control treatment in improving lung imaging findings, inhibiting the exacerbation of pneumonia, promoting a virus negative conversion, and shortening the disease course at different levels of severity [92]. |
T127 | 1008-1167 | Sentence | denotes | More recently, hydroxychloroquine was demonstrated to be more 3-times more potent than chloroquine in an in vitro study based on pharmacokinetic models (PBPK). |
T128 | 1168-1358 | Sentence | denotes | An oral loading dose of 400 mg twice daily, followed by a maintenance dose of 200 mg given twice daily for 4 days seems to be the best option for the management of SARS-CoV-2 infection [93]. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T73 | 886-895 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32205186-16115318-4826916 | 243-245 | 16115318 | denotes | 88 |
32205186-16439323-4826917 | 255-257 | 16439323 | denotes | 90 |